Patents Examined by Lea S O'Brien
  • Antibodies that bind human C6 and uses thereof
    Patent number: 12194091
    Abstract: Isolated monoclonal antibodies that bind to human complement component C6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.
    Type: Grant
    Filed: February 14, 2023
    Date of Patent: January 14, 2025
    Assignee: REGENESANCE B.V.
    Inventors: Frank Baas, Marc A. Van Dijk
  • IL3Ralpha antibodies and uses thereof
    Patent number: 12187802
    Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: January 7, 2025
    Assignee: Stemline Therapeutics, Inc.
    Inventor: Ivan Bergstein
  • Humanized anti-human neurotensin receptor 1 antibodies and their uses
    Patent number: 12091454
    Abstract: A humanized anti-neurotensin receptor 1 (NTSR1) antibody or an antigen-binding fragment thereof. Also, a method for treating, prophylactic treating and/or preventing diseases and/or disorders caused by or related to NTSR1 activity and/or signaling, and a method or kit for detecting NTSR1 in a sample.
    Type: Grant
    Filed: December 28, 2022
    Date of Patent: September 17, 2024
    Assignees: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Cheng-Chou Yu, Shu-Ping Yeh, Chao-Yang Huang, Szu-Liang Lai, Shih-Liang Hsiao, Mei-Ling Hou, Tzung-Jie Yang, Wei-Ting Sun, Liang-Yu Hsia, Andrew Yueh, Chiung-Tong Chen, Ren-Huang Wu, Pei-Shan Wu, Han-Shu Hu, Tzu-Chin Wu, Jia-Ni Tian
  • Antibodies specific to delta 1 chain of T cell receptor
    Patent number: 12084500
    Abstract: Disclosed herein are antibodies specific to a delta-1 chain of a ?? T cell receptor and methods of using such for modulating ?? T cell bioactivity. Such anti-Delta 1 antibodies may also be used to treat diseases associated with ?? T cell activation, such as solid tumors, or for detecting presence of ??1 T cells.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: September 10, 2024
    Assignees: New York University, PureTech LYT, Inc.
    Inventors: Shohei Koide, George Miller, Akiko Koide, Tatyana Panchenko, Takamitsu Hattori, Aleksandra Filipovic, Eric Elenko, Joseph Bolen
  • Anti-ULBP6 antibodies
    Patent number: 12060426
    Abstract: The present disclosure relates to a ULBP6 binding protein that inhibits the interaction between ULBP6 and NKG2D, and methods of treating cancer with said ULBP6 binding protein.
    Type: Grant
    Filed: April 28, 2023
    Date of Patent: August 13, 2024
    Assignee: 23andMe, Inc.
    Inventors: Joel Benjamin, Shashank Bharill, I-Ling Chen, Yu Chen, Wei-Jen Chung, Zahra Bahrami Dizicheh, Germaine Fuh, Patrick Koenig, Yujie Liu, Mauro Poggio, Shruti Yadav, Ping-Chiao Tsai, Claus Spitzfaden
  • Humanized anti-human CTLA4 monoclonal antibody, preparation method therefor and use thereof
    Patent number: 12037396
    Abstract: The present invention relates to a humanized anti-human CTLA4 monoclonal antibody. The present invention also relates to a preparation method and application of the humanized anti-human CTLA4 monoclonal antibody.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: July 16, 2024
    Assignee: Nanjing GenScript Biotech Co., Ltd.
    Inventors: Liusong Yin, Tielin Zhou, Zhuo Fang, Yanling Mi, Chunchen Wu